Cornell University Hospital for Animals, College of Veterinary Medicine, Ithaca, New York.
Veterinary Specialty Hospital of the Carolinas, Cary, North Carolina.
J Vet Emerg Crit Care (San Antonio). 2021 May;31(3):371-379. doi: 10.1111/vec.13037. Epub 2021 Feb 17.
To evaluate characteristics of septic shock patients treated with hydrocortisone (HC) due to suspicion of critical illness-related corticosteroid insufficiency (CIRCI) as compared to septic shock patients without suspicion of CIRCI.
Retrospective study between February 2010 and October 2017.
University teaching hospital ICU.
Data were collected for 47 dogs with septic shock. Twenty-one dogs were treated with HC (HC-treated) due to suspicion of CIRCI. Twenty-six dogs did not receive HC (non-HC-treated).
HC was administered either as an intermittent IV bolus or as a constant rate infusion (CRI) to those patients with suspected CIRCI.
Significantly higher baseline APPLE scores and predicted mortality were detected in the HC-treated patients compared to non-HC-treated patients (0.87 vs 0.44 for predicted mortality, P = 0.039). Patients in the HC-treated group were on more vasopressors and cardiotonics than those in the non-HC-treated group (2.5 vs 1.5, P <0 .001). All patients initially responded to vasopressor administration, with average time to resolution of hypotension being 90 minutes for the HC-treated group compared to 60 minutes for the non-HC-treated group (P = 0.640). However, HC-treated patients took significantly longer to have a sustained resolution (a systolic blood pressure > 90 mm Hg or a mean blood pressure > 65 mm Hg for at least 4 h) of their hypotension after starting vasopressors, as compared to their non-HC-treated counterparts (8.5 vs 4 h, P = 0.001). Three (14.3%) HC-treated patients survived to discharge compared to 9 (34.6%) non-HC-treated patients, but this was not statistically significant.
HC-treated patients had a higher baseline risk of mortality than non-HC-treated patients. There was no significant difference in survival between the HC-treated and non-HC-treated septic shock patients. Further studies are needed to evaluate the use of HC in patients with suspected CIRCI.
评估因疑似危重病相关皮质激素不足(CIRCI)而接受氢化可的松(HC)治疗的脓毒性休克患者与疑似 CIRCI 患者的特征。
2010 年 2 月至 2017 年 10 月间的回顾性研究。
大学教学医院 ICU。
共收集了 47 只患有脓毒性休克的狗的数据。21 只狗因疑似 CIRCI 而接受 HC 治疗(HC 治疗组)。26 只狗未接受 HC 治疗(非 HC 治疗组)。
对疑似 CIRCI 患者给予 HC 间歇性静脉推注或持续输注(CRI)。
与非 HC 治疗组相比,HC 治疗组患者的基线 APPLE 评分和预测死亡率明显更高(预测死亡率分别为 0.87 和 0.44,P=0.039)。HC 治疗组患者接受的血管加压药和强心药比非 HC 治疗组多(2.5 比 1.5,P<0.001)。所有患者最初对血管加压药治疗均有反应,HC 治疗组低血压缓解时间平均为 90 分钟,而非 HC 治疗组为 60 分钟(P=0.640)。然而,与非 HC 治疗组相比,HC 治疗组的患者在开始使用血管加压药后,需要更长的时间才能持续缓解低血压(收缩压>90mmHg 或平均血压>65mmHg 至少 4 小时)(8.5 小时比 4 小时,P=0.001)。与非 HC 治疗组相比,有 3 只(14.3%)HC 治疗组的患者存活至出院,而有 9 只(34.6%)非 HC 治疗组的患者存活至出院,但这并无统计学意义。
与非 HC 治疗组相比,HC 治疗组患者的基线死亡率更高。HC 治疗组和非 HC 治疗组的脓毒性休克患者的存活率无显著差异。需要进一步研究来评估 HC 在疑似 CIRCI 患者中的应用。